Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

518.29 -20.00 (-3.72%)
Streaming Delayed Price Updated: 12:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,325,087
Open 536.00
Bid (Size) 518.15 (1)
Ask (Size) 518.41 (4)
Prev. Close 538.29
Today's Range 517.10 - 537.34
52wk Range 302.14 - 601.84
Shares Outstanding N/A
Dividend Yield 0.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Point Biopharma Stock Nearly Doubles On Eli Lilly Deal
Eli Lilly is spending $1.4 billion on buying Point Biopharma Global Inc. Point Biopharma is a radiopharmaceutical company focused on cancer treatment. 
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Vericity, Inc. (Nasdaq - VERY), POINT Biopharma Global, Inc. (Nasdaq - PNT), Blue Apron Holdings, Inc. (Nasdaq - APRN), Chico’s FAS, Inc. (NYSE - CHS)
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
+42.00%
+42.00%
1 Month
-7.15%
-7.15%
3 Month
+12.32%
+12.32%
6 Month
+47.77%
+47.77%
1 Year
+61.18%
+61.18%

More News

Read More
S&P 500 Forecast: Stocks Drop As Treasury Yields Surge
Via Talk Markets
Topics Stocks
Exposures US Equities
Analyst Ratings for Eli Lilly
Via Benzinga
FDA Declines To Approve Eli Lilly's Eczema Drug
Via Benzinga
Exposures Product Safety
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Falls Over 100 Points; McCormick Sales Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Point Biopharma Stock Launches 84% On Eli Lilly's $1.4 Billion Takeover
Via Investor's Business Daily
Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today?
Via Benzinga
Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?
Via Benzinga
Why Is Point Biopharma (PNT) Stock Up 84% Today?
Via InvestorPlace
Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Up Monday
Via The Motley Fool
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
Via InvestorPlace
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
Via InvestorPlace
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
These Market Experts See a Downturn Coming: 2 Defensive Index Funds That Are Proven Moneymakers to Buy Now
Via The Motley Fool
What A Government Shutdown Could Mean For You
Via Benzinga
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Shares of Structure Therapeutics Are Soaring on Friday
Via The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
Via Investor's Business Daily
Eli Lilly, Former Employee Settle Lawsuit Concerning Manufacturing Dispute
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.